Medline Inc. - Class A common stock (MDLN)
35.88
-0.54 (-1.47%)
NASDAQ· Last Trade: Jun 18th, 4:28 PM EDT
Detailed Quote
| Previous Close | 36.42 |
|---|---|
| Open | 36.14 |
| Bid | 35.88 |
| Ask | 35.93 |
| Day's Range | 35.27 - 36.70 |
| 52 Week Range | 32.81 - 50.88 |
| Volume | 15,046,342 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 14,306,930 |
Chart
News & Press Releases
NEW YORK, NY - June 18, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN).
Via NewMediaWire · June 18, 2026
NEW YORK, NY - June 18, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN).
Via TheNewswire.com · June 18, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · June 17, 2026
NEW YORK, NY - June 17, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN).
Via TheNewswire.com · June 17, 2026
Medline (NASDAQ:MDLN) Q1 Earnings: Revenue Beats, But Profits Slip on Tariff and Cost Pressureschartmill.com
Via Chartmill · May 6, 2026
Medline Inc. (NASDAQ:MDLN) Reports Q4 Revenue Beat but EPS Miss Amid Margin Pressurechartmill.com
Via Chartmill · February 25, 2026
NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Medline Industries, Inc. (“Medline” or the “Company”) (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · June 16, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · June 16, 2026
NEW YORK, NY - June 16, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN).
Via TheNewswire.com · June 16, 2026
NEW YORK, NY - June 15, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN).
Via TheNewswire.com · June 15, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · June 15, 2026
LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medline Inc. (“Medline” or “the Company”) (NASDAQ: MDLN) for violations of the securities laws.
By Schall Law · Via GlobeNewswire · June 10, 2026
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Medline Industries, Inc. (“Medline” or the “Company”) (NASDAQ: MDLN) investors concerning the Company’s possible violations of the federal securities laws.
By Glancy Prongay Wolke & Rotter LLP · Via Business Wire · June 9, 2026
Law Offices of Howard G. Smith announces an investigation on behalf of Medline Industries, Inc. (“Medline” or the “Company”) (NASDAQ: MDLN) investors concerning the Company’s possible violations of federal securities laws.
By Law Offices of Howard G. Smith · Via Business Wire · June 9, 2026
The Law Offices of Frank R. Cruz announces an investigation of Medline Industries, Inc. (“Medline” or the “Company”) (NASDAQ: MDLN) on behalf of investors concerning the Company’s possible violations of federal securities laws.
By The Law Offices of Frank R. Cruz · Via Business Wire · June 8, 2026
Is something seriously wrong with the automation expert, or is this a market overreaction and an opportunity to buy?
Via The Motley Fool · June 8, 2026
NORTHFIELD, Ill., May 28, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that it has closed its upsized secondary offering of 72,554,594 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $37.00 per share. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 10,883,189 shares of Medline’s Class A common stock.
By Medline Inc. · Via GlobeNewswire · May 28, 2026
NORTHFIELD, Ill., May 27, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that members of the executive leadership team will be participating in the following investor conferences.
By Medline Inc. · Via GlobeNewswire · May 27, 2026
NORTHFIELD, Ill., May 21, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its upsized secondary offering of 72,554,594 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $37.00 per share. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 10,883,189 shares of Medline’s Class A common stock. The offering is expected to close on May 28, 2026, subject to customary closing conditions.
By Medline Inc. · Via GlobeNewswire · May 21, 2026
This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.
Via The Motley Fool · May 20, 2026
NORTHFIELD, Ill., May 20, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) have commenced an underwritten public offering of 60,000,000 shares of Medline’s Class A common stock pursuant to a registration statement filed with the Securities and Exchange Commission (the “SEC”). Additionally, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 9,000,000 shares of Medline’s Class A common stock.
By Medline Inc. · Via GlobeNewswire · May 20, 2026
NORTHFIELD, Ill., May 06, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline” or the “Company”) (Nasdaq: MDLN), the largest provider of medical-surgical (“med-surg”) products and supply chain solutions serving all points of care3, today reported its operating results for the three months ended March 28, 2026.
By Medline Inc. · Via GlobeNewswire · May 6, 2026
NORTHFIELD, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that it has closed its secondary offering of 86,250,000 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $41.00 per share, including the full exercise by the underwriters of their option to purchase up to an additional 11,250,000 shares of Medline’s Class A common stock.
By Medline Inc. · Via GlobeNewswire · March 10, 2026
NORTHFIELD, Ill., March 04, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of a previously announced secondary offering of 75,000,000 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $41.00 per share. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 11,250,000 shares of Medline’s Class A common stock. The offering is expected to close on March 10, 2026, subject to customary closing conditions.
By Medline Inc. · Via GlobeNewswire · March 4, 2026
NORTHFIELD, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) have commenced an underwritten public offering of 75,000,000 shares of Medline’s Class A common stock pursuant to a registration statement filed with the Securities and Exchange Commission (the “SEC”). Additionally, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 11,250,000 shares of Medline’s Class A common stock.
By Medline Inc. · Via GlobeNewswire · March 3, 2026